The stock market is booming in India and stocks are up over 8% this year.
The S&P 500 is up nearly 6% year-on-year, and the Nasdaq Composite is up 4.7%.
India’s largest pharmacy chain, India Pharmacopoeia (IPS), is leading the rally, with its share price up more than 50% this week.
The shares have been up more recently than the broader market.
It is a strong sign for India’s pharma industry, which is already facing the challenge of growing more than 500 million prescriptions a year.
India is also the world’s largest importer of prescription drugs, and pharma firms in India have seen demand for drugs soar in recent years.
But for many Indian consumers, the stock market has become a place where the government keeps a close eye on the quality of drugs.
That has led to a number of government interventions, including restrictions on drug imports and bans on foreign pharmaceutical companies buying Indian drugs.
So, the pharma sector has been watching closely the stock markets for signs that the government may be easing its grip on the industry.
“We are expecting a slowdown in the share price and we are seeing some companies that are getting ready to sell,” said Anupam Chatterjee, chief executive officer of the India Pharmacy Manufacturers Association.
This has led the government to put in place a series of regulations aimed at improving quality control.
The government’s decision to ban imports of some of India’s best-selling drugs has also led to some firms cutting prices.
The government has also set up a new regulator, the Centre for Drug Evaluation and Research (CDER), to examine the effectiveness of its drug policy and take action when there is a problem.
However, the pharmaceutical sector is also seeing a rise in generic drugs, which are cheaper to manufacture and cheaper to distribute.
India has some of the world´s lowest drug prices, and there are growing concerns that generic drugs may be hurting the health of patients.
Last month, the Supreme Court said generic drugs would not be allowed to be used for patients in the first six months of next year.
This means that generic medicines are currently being sold for less than their official price.
Health ministry data suggests that India has the second lowest rate of cancer deaths in the world after India.
The Indian pharma and health industries are facing the challenges of growing a global brand without having a national presence.
India has been the most innovative in manufacturing pharmaceuticals in the global market.
In the last few years, pharmaceutical companies have moved from manufacturing drugs in small factories to producing them in big facilities, where more drugs can be manufactured at lower costs.
Despite this, there are still hurdles to getting generic drugs onto the market in India.
In April, India banned the import of some generic drugs to prevent the spread of a rare, deadly form of hepatitis C that was found in some imported Indian products.
One of the reasons for the ban was a lack of testing facilities, and it has also slowed the production of generic drugs in India, which has been one of the biggest markets for the drugs.
This has caused some manufacturers to look elsewhere for cheaper and easier ways to produce their drugs.